Holen Sie sich die Stockscreener-App
1.96
3.16%
0.06
Vorhandelsmarkt:
1.97
0.01
+0.51%
Schlusskurs vom Vortag:
$1.90
Offen:
$1.9
24-Stunden-Volumen:
6.36M
Relative Volume:
0.64
Marktkapitalisierung:
$676.50M
Einnahmen:
$22,000
Nettoeinkommen (Verlust:
$-173.76M
KGV:
-2.5518
EPS:
-0.7681
Netto-Cashflow:
$-109.53M
1W Leistung:
+10.11%
1M Leistung:
-2.00%
6M Leistung:
+38.03%
1J Leistung:
+50.77%
1-Tages-Spanne:
$1.90
$2.056
1-Wochen-Bereich:
$1.75
$2.10
52-Wochen-Spanne:
$0.9842
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.96 | 669.60M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-04-10 | Fortgesetzt | Jefferies | Buy |
| 2026-01-09 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? - Yahoo Finance
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio - Insider Monkey
A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test - The Business Journals
CMO Roberts to succeed Chang as Allogene CEO - BioCentury
Certain Restricted Stock Units of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
Certain Common Stock of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
Allogene Therapeutics Names Zachary Roberts as New CEO - The Globe and Mail
Allogene Therapeutics, Inc. 8-K SEC Filing May 28, 2026: Company Details, Common Stock, and Exchange Information - Minichart
Allogene CEO to step down; Agios drug fails key test - BioPharma Dive
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Allogene Therapeutics (ALLO) Announces Leadership Transition - GuruFocus
Allogene Therapeutics names Zachary Roberts CEO in planned succession - MSN
Allogene Therapeutics names Zachary Roberts as new CEO By Investing.com - Investing.com South Africa
Allogene Therapeutics CEO David Chang Steps Down - marketscreener.com
Allogene Therapeutics announces planned CEO succession - marketscreener.com
Allogene Therapeutics names Zachary Roberts as new CEO - Investing.com
Zachary Roberts named Allogene President and CEO, David Chang stepping down - TradingView
Allogene Therapeutics (ALLO) elevates Zachary Roberts to CEO with major equity awards - Stock Titan
Allogene Therapeutics, Inc. Announces CEO Changes - marketscreener.com
Allogene Therapeutics (ALLO) Surges 6%: Can the Biotech Reclaim Key Resistance?On Balance Volume - thelegaladvocate.com
ALLO Stock Steadies As Cash Runway Extends To 2029 On Trial Progress - StocksToTrade
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Cancer cell therapy firm Allogene lines up three investor talks - Stock Titan
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Allogene Therapeutics posts narrower-than-expected loss in Q1 - MSN
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment - Traders Union
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss - Investing.com UK
ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M - MSN
Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy - Traders Union
Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO) - Stock Titan
Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake - Stock Titan
Allogene Therapeutics | SCHEDULE 13G/A: Others - Moomoo
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $7 to $14 - Moomoo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO) - The Globe and Mail
Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO) - The Globe and Mail
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 7.7%Here's What Happened - MarketBeat
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1 - The Globe and Mail
Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):